NRx Pharmaceuticals' (NRXP) Buy Rating Reaffirmed at D. Boral Capital

Key Points

• NRx Pharmaceuticals has received a reaffirmed "buy" rating from D. Boral Capital with a target price of $34.00, amidst a mixed consensus from other analysts.
• The stock maintains a consensus rating of "Moderate Buy" with a projected price target of $34.50, highlighting differing opinions among analysts, with four buy ratings, one hold, and one sell.
• NRx Pharmaceuticals recently reported a quarterly loss of ($0.98) earnings per share, significantly missing estimates, and is forecasted to post ($1.75) EPS for the current fiscal year.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $34.00 target price on the stock.

A number of other equities research analysts also recently issued reports on NRXP. Weiss Ratings reiterated a "sell (d-)" rating on shares of NRx Pharmaceuticals in a research report on Wednesday, October 8th. BTIG Research restated a "buy" rating on shares of NRx Pharmaceuticals in a research report on Monday, August 25th. Zacks Research upgraded NRx Pharmaceuticals to a "hold" rating in a research report on Wednesday, September 10th. Finally, HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, October 16th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.50.

NRx Pharmaceuticals Trading Up 4.1%

NRXP stock opened at $3.31 on Tuesday. The firm has a 50 day moving average of $2.92 and a 200-day moving average of $2.75. NRx Pharmaceuticals has a 12-month low of $1.12 and a 12-month high of $6.01. The company has a market cap of $65.57 million, a price-to-earnings ratio of -1.48 and a beta of 1.74.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last posted its quarterly earnings results on Monday, August 18th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.67). Sell-side analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

An institutional investor recently raised its position in NRx Pharmaceuticals stock. Geode Capital Management LLC grew its stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) by 27.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 172,255 shares of the company's stock after buying an additional 37,598 shares during the period. Geode Capital Management LLC owned 1.00% of NRx Pharmaceuticals worth $562,000 as of its most recent SEC filing. Institutional investors own 4.27% of the company's stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.